antiviral news
Press Releases in the global landscape
May 13, 2026
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare
Read More »
May 4, 2026
Nirmatrelvir–ritonavir does not improve severe outcomes in adults vaccinated against COVID-19
Study found nirmatrelvir–ritonavir did not reduce severe outcomes in vaccinated COVID-19 patients, though symptom recovery improved.
Read More »
Apr 23, 2026
St. Michael’s Hospital’s Upstream Lab uncovers new evidence which could shape decisions on Paxlovid use for COVID-19
St. Michael’s Hospital’s Upstream Lab uncovers new evidence which could shape decisions on Paxlovid use for COVID-19
Read More »
Apr 22, 2026
If It's COVID, Paxlovid? Studies Suggest a Rethink These Days
Studies suggest Paxlovid may not prevent severe COVID-19 outcomes in vaccinated individuals but could reduce recovery time and viral load.
Read More »
Mar 24, 2026
ACP updates outpatient COVID-19 treatment guidance
The American College of Physicians updated outpatient COVID-19 treatment guidelines, outlining best practices for medication use in confirmed cases.
Read More »
Mar 24, 2026
Japan approves preventive use of oral COVID drug Xocova in world first
Japan approved the preventive use of the oral COVID-19 antiviral Xocova, marking the first authorization of its kind globally.
Read More »